Status of Metabolomic Measurement for Insights in Alzheimer's Disease Progression-What Is Missing?
Alzheimer's disease (AD) is an aging-related neurodegenerative disease, leading to the progressive loss of memory and other cognitive functions. As there is still no cure for AD, the growth in the number of susceptible individuals represents a major emerging threat to public health. Currently,...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2023-03, Vol.24 (5), p.4960 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 5 |
| container_start_page | 4960 |
| container_title | International journal of molecular sciences |
| container_volume | 24 |
| creator | Yin, Chunyuan Harms, Amy C Hankemeier, Thomas Kindt, Alida de Lange, Elizabeth C M |
| description | Alzheimer's disease (AD) is an aging-related neurodegenerative disease, leading to the progressive loss of memory and other cognitive functions. As there is still no cure for AD, the growth in the number of susceptible individuals represents a major emerging threat to public health. Currently, the pathogenesis and etiology of AD remain poorly understood, while no efficient treatments are available to slow down the degenerative effects of AD. Metabolomics allows the study of biochemical alterations in pathological processes which may be involved in AD progression and to discover new therapeutic targets. In this review, we summarized and analyzed the results from studies on metabolomics analysis performed in biological samples of AD subjects and AD animal models. Then this information was analyzed by using MetaboAnalyst to find the disturbed pathways among different sample types in human and animal models at different disease stages. We discuss the underlying biochemical mechanisms involved, and the extent to which they could impact the specific hallmarks of AD. Then we identify gaps and challenges and provide recommendations for future metabolomics approaches to better understand AD pathogenesis. |
| doi_str_mv | 10.3390/ijms24054960 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10003384</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A751926162</galeid><sourcerecordid>A751926162</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-efed920d55a7b6705a132295b12fd57e763c34da3db24e52e1c88580126fc9373</originalsourceid><addsrcrecordid>eNptksFvFSEQxjdGY2v15tmQeNBDtw6wsMupealWX9JGEzUeCcvO7uNlFyrsmuhfLy-t7WtjODADv_lg4CuKlxROOFfwzm2nxCoQlZLwqDikFWMlgKwf78UHxbOUtgCMM6GeFgdcqhwreli0X2czL4mEnlzibNowhsnZHJu0RJzQz6QPkax9csNmTsR5shr_bNBNGN8k8t6lTCL5EsMQMSUXfPljY2ayTuTS5dwPp8-LJ70ZE764mY-K7-cfvp19Ki8-f1yfrS5KWzUwl9hjpxh0Qpi6lTUIQzljSrSU9Z2osZbc8qozvGtZhYIhtU0jGqBM9lbxmh8Vp9e6V0s7YWfz3aMZ9VV0k4m_dTBO39_xbqOH8EtTAOC8qbLC2xuFGH4umGY9uWRxHI3HsCTN6kaCqgSIjL5-gG7DEn3ub0cJxlgD8o4azIja-T7kg-1OVK9qQRWTVLJMnfyHyqPD_BfBY-_y-r2C4-sCG0NKEfvbJinonSn0viky_mr_YW7hfy7gfwH-xbFb</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2785222806</pqid></control><display><type>article</type><title>Status of Metabolomic Measurement for Insights in Alzheimer's Disease Progression-What Is Missing?</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Yin, Chunyuan ; Harms, Amy C ; Hankemeier, Thomas ; Kindt, Alida ; de Lange, Elizabeth C M</creator><creatorcontrib>Yin, Chunyuan ; Harms, Amy C ; Hankemeier, Thomas ; Kindt, Alida ; de Lange, Elizabeth C M</creatorcontrib><description>Alzheimer's disease (AD) is an aging-related neurodegenerative disease, leading to the progressive loss of memory and other cognitive functions. As there is still no cure for AD, the growth in the number of susceptible individuals represents a major emerging threat to public health. Currently, the pathogenesis and etiology of AD remain poorly understood, while no efficient treatments are available to slow down the degenerative effects of AD. Metabolomics allows the study of biochemical alterations in pathological processes which may be involved in AD progression and to discover new therapeutic targets. In this review, we summarized and analyzed the results from studies on metabolomics analysis performed in biological samples of AD subjects and AD animal models. Then this information was analyzed by using MetaboAnalyst to find the disturbed pathways among different sample types in human and animal models at different disease stages. We discuss the underlying biochemical mechanisms involved, and the extent to which they could impact the specific hallmarks of AD. Then we identify gaps and challenges and provide recommendations for future metabolomics approaches to better understand AD pathogenesis.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms24054960</identifier><identifier>PMID: 36902391</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Advertising executives ; Alzheimer Disease - metabolism ; Alzheimer's disease ; Animal cognition ; Animal models ; Animals ; Biological properties ; Biomarkers ; Brain research ; Cholesterol ; Chromatography ; Cognition ; Development and progression ; Disease Models, Animal ; Etiology ; Health aspects ; Humans ; Laboratories ; Lipids ; Mass spectrometry ; Measurement ; Metabolism ; Metabolites ; Metabolomics ; Metabolomics - methods ; Molecular weight ; Neurodegenerative Diseases ; NMR ; Nuclear magnetic resonance ; Pathogenesis ; Proteins ; Public health ; Reproducibility ; Review ; Scientific imaging ; Target marketing ; Therapeutic targets ; Volatility</subject><ispartof>International journal of molecular sciences, 2023-03, Vol.24 (5), p.4960</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-efed920d55a7b6705a132295b12fd57e763c34da3db24e52e1c88580126fc9373</citedby><cites>FETCH-LOGICAL-c480t-efed920d55a7b6705a132295b12fd57e763c34da3db24e52e1c88580126fc9373</cites><orcidid>0000-0001-6551-6030 ; 0000-0002-2931-4295 ; 0000-0001-7871-2073 ; 0000-0002-4017-9389 ; 0000-0001-7904-7124</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003384/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10003384/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36902391$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yin, Chunyuan</creatorcontrib><creatorcontrib>Harms, Amy C</creatorcontrib><creatorcontrib>Hankemeier, Thomas</creatorcontrib><creatorcontrib>Kindt, Alida</creatorcontrib><creatorcontrib>de Lange, Elizabeth C M</creatorcontrib><title>Status of Metabolomic Measurement for Insights in Alzheimer's Disease Progression-What Is Missing?</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>Alzheimer's disease (AD) is an aging-related neurodegenerative disease, leading to the progressive loss of memory and other cognitive functions. As there is still no cure for AD, the growth in the number of susceptible individuals represents a major emerging threat to public health. Currently, the pathogenesis and etiology of AD remain poorly understood, while no efficient treatments are available to slow down the degenerative effects of AD. Metabolomics allows the study of biochemical alterations in pathological processes which may be involved in AD progression and to discover new therapeutic targets. In this review, we summarized and analyzed the results from studies on metabolomics analysis performed in biological samples of AD subjects and AD animal models. Then this information was analyzed by using MetaboAnalyst to find the disturbed pathways among different sample types in human and animal models at different disease stages. We discuss the underlying biochemical mechanisms involved, and the extent to which they could impact the specific hallmarks of AD. Then we identify gaps and challenges and provide recommendations for future metabolomics approaches to better understand AD pathogenesis.</description><subject>Advertising executives</subject><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer's disease</subject><subject>Animal cognition</subject><subject>Animal models</subject><subject>Animals</subject><subject>Biological properties</subject><subject>Biomarkers</subject><subject>Brain research</subject><subject>Cholesterol</subject><subject>Chromatography</subject><subject>Cognition</subject><subject>Development and progression</subject><subject>Disease Models, Animal</subject><subject>Etiology</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Laboratories</subject><subject>Lipids</subject><subject>Mass spectrometry</subject><subject>Measurement</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Metabolomics</subject><subject>Metabolomics - methods</subject><subject>Molecular weight</subject><subject>Neurodegenerative Diseases</subject><subject>NMR</subject><subject>Nuclear magnetic resonance</subject><subject>Pathogenesis</subject><subject>Proteins</subject><subject>Public health</subject><subject>Reproducibility</subject><subject>Review</subject><subject>Scientific imaging</subject><subject>Target marketing</subject><subject>Therapeutic targets</subject><subject>Volatility</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptksFvFSEQxjdGY2v15tmQeNBDtw6wsMupealWX9JGEzUeCcvO7uNlFyrsmuhfLy-t7WtjODADv_lg4CuKlxROOFfwzm2nxCoQlZLwqDikFWMlgKwf78UHxbOUtgCMM6GeFgdcqhwreli0X2czL4mEnlzibNowhsnZHJu0RJzQz6QPkax9csNmTsR5shr_bNBNGN8k8t6lTCL5EsMQMSUXfPljY2ayTuTS5dwPp8-LJ70ZE764mY-K7-cfvp19Ki8-f1yfrS5KWzUwl9hjpxh0Qpi6lTUIQzljSrSU9Z2osZbc8qozvGtZhYIhtU0jGqBM9lbxmh8Vp9e6V0s7YWfz3aMZ9VV0k4m_dTBO39_xbqOH8EtTAOC8qbLC2xuFGH4umGY9uWRxHI3HsCTN6kaCqgSIjL5-gG7DEn3ub0cJxlgD8o4azIja-T7kg-1OVK9qQRWTVLJMnfyHyqPD_BfBY-_y-r2C4-sCG0NKEfvbJinonSn0viky_mr_YW7hfy7gfwH-xbFb</recordid><startdate>20230301</startdate><enddate>20230301</enddate><creator>Yin, Chunyuan</creator><creator>Harms, Amy C</creator><creator>Hankemeier, Thomas</creator><creator>Kindt, Alida</creator><creator>de Lange, Elizabeth C M</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-6551-6030</orcidid><orcidid>https://orcid.org/0000-0002-2931-4295</orcidid><orcidid>https://orcid.org/0000-0001-7871-2073</orcidid><orcidid>https://orcid.org/0000-0002-4017-9389</orcidid><orcidid>https://orcid.org/0000-0001-7904-7124</orcidid></search><sort><creationdate>20230301</creationdate><title>Status of Metabolomic Measurement for Insights in Alzheimer's Disease Progression-What Is Missing?</title><author>Yin, Chunyuan ; Harms, Amy C ; Hankemeier, Thomas ; Kindt, Alida ; de Lange, Elizabeth C M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-efed920d55a7b6705a132295b12fd57e763c34da3db24e52e1c88580126fc9373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Advertising executives</topic><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer's disease</topic><topic>Animal cognition</topic><topic>Animal models</topic><topic>Animals</topic><topic>Biological properties</topic><topic>Biomarkers</topic><topic>Brain research</topic><topic>Cholesterol</topic><topic>Chromatography</topic><topic>Cognition</topic><topic>Development and progression</topic><topic>Disease Models, Animal</topic><topic>Etiology</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Laboratories</topic><topic>Lipids</topic><topic>Mass spectrometry</topic><topic>Measurement</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Metabolomics</topic><topic>Metabolomics - methods</topic><topic>Molecular weight</topic><topic>Neurodegenerative Diseases</topic><topic>NMR</topic><topic>Nuclear magnetic resonance</topic><topic>Pathogenesis</topic><topic>Proteins</topic><topic>Public health</topic><topic>Reproducibility</topic><topic>Review</topic><topic>Scientific imaging</topic><topic>Target marketing</topic><topic>Therapeutic targets</topic><topic>Volatility</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yin, Chunyuan</creatorcontrib><creatorcontrib>Harms, Amy C</creatorcontrib><creatorcontrib>Hankemeier, Thomas</creatorcontrib><creatorcontrib>Kindt, Alida</creatorcontrib><creatorcontrib>de Lange, Elizabeth C M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yin, Chunyuan</au><au>Harms, Amy C</au><au>Hankemeier, Thomas</au><au>Kindt, Alida</au><au>de Lange, Elizabeth C M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Status of Metabolomic Measurement for Insights in Alzheimer's Disease Progression-What Is Missing?</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2023-03-01</date><risdate>2023</risdate><volume>24</volume><issue>5</issue><spage>4960</spage><pages>4960-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>Alzheimer's disease (AD) is an aging-related neurodegenerative disease, leading to the progressive loss of memory and other cognitive functions. As there is still no cure for AD, the growth in the number of susceptible individuals represents a major emerging threat to public health. Currently, the pathogenesis and etiology of AD remain poorly understood, while no efficient treatments are available to slow down the degenerative effects of AD. Metabolomics allows the study of biochemical alterations in pathological processes which may be involved in AD progression and to discover new therapeutic targets. In this review, we summarized and analyzed the results from studies on metabolomics analysis performed in biological samples of AD subjects and AD animal models. Then this information was analyzed by using MetaboAnalyst to find the disturbed pathways among different sample types in human and animal models at different disease stages. We discuss the underlying biochemical mechanisms involved, and the extent to which they could impact the specific hallmarks of AD. Then we identify gaps and challenges and provide recommendations for future metabolomics approaches to better understand AD pathogenesis.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36902391</pmid><doi>10.3390/ijms24054960</doi><orcidid>https://orcid.org/0000-0001-6551-6030</orcidid><orcidid>https://orcid.org/0000-0002-2931-4295</orcidid><orcidid>https://orcid.org/0000-0001-7871-2073</orcidid><orcidid>https://orcid.org/0000-0002-4017-9389</orcidid><orcidid>https://orcid.org/0000-0001-7904-7124</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2023-03, Vol.24 (5), p.4960 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10003384 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Advertising executives Alzheimer Disease - metabolism Alzheimer's disease Animal cognition Animal models Animals Biological properties Biomarkers Brain research Cholesterol Chromatography Cognition Development and progression Disease Models, Animal Etiology Health aspects Humans Laboratories Lipids Mass spectrometry Measurement Metabolism Metabolites Metabolomics Metabolomics - methods Molecular weight Neurodegenerative Diseases NMR Nuclear magnetic resonance Pathogenesis Proteins Public health Reproducibility Review Scientific imaging Target marketing Therapeutic targets Volatility |
| title | Status of Metabolomic Measurement for Insights in Alzheimer's Disease Progression-What Is Missing? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T04%3A32%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Status%20of%20Metabolomic%20Measurement%20for%20Insights%20in%20Alzheimer's%20Disease%20Progression-What%20Is%20Missing?&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=Yin,%20Chunyuan&rft.date=2023-03-01&rft.volume=24&rft.issue=5&rft.spage=4960&rft.pages=4960-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms24054960&rft_dat=%3Cgale_pubme%3EA751926162%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2785222806&rft_id=info:pmid/36902391&rft_galeid=A751926162&rfr_iscdi=true |